Cytokines and Immune Signaling

Why cytokines matter

• They are the language of immunity. No immune cell fights alone. A macrophage that meets bacterial lipopolysaccharide secretes IL-1, IL-6, and TNF-α within an hour; those proteins recruit neutrophils, raise a fever, and prime the liver to make acute-phase proteins like C-reactive protein. Cytokines are how one sensing cell mobilizes the whole system.
• They decide the flavor of the response. The same naive CD4 T cell becomes a Th1 (IFN-γ, fights intracellular pathogens), Th2 (IL-4/IL-5/IL-13, fights worms and drives allergy), Th17 (IL-17, fights fungi and extracellular bacteria), or regulatory T cell depending entirely on which cytokines it saw during priming. IL-12 pushes Th1; IL-4 pushes Th2; IL-6 plus TGF-β pushes Th17.
• Interferons are the antiviral alarm. A virus-infected cell releases type I interferon (IFN-α/β), which triggers hundreds of interferon-stimulated genes in neighbors — degrading viral RNA, blocking translation, and raising MHC-I so infected cells become visible to cytotoxic T cells. Inborn errors of the type I IFN pathway predispose to life-threatening viral disease.
• Chemokines are the GPS. Cytokines tell cells what to do; chemokines tell them where to go. A gradient of CXCL8 (IL-8) draws neutrophils out of blood into infected tissue; CCL19/CCL21 guide dendritic cells and T cells into lymph nodes via CCR7. HIV famously hijacks the chemokine receptor CCR5 as its co-receptor to enter T cells.
• They are the biggest drug class in immunology. Anti-TNF biologics (adalimumab/Humira, infliximab, etanercept) treat rheumatoid arthritis, Crohn's, psoriasis, and more; anti-IL-6R (tocilizumab), anti-IL-17 (secukinumab), anti-IL-23 (ustekinumab, risankizumab), and JAK inhibitors (tofacitinib, baricitinib, ruxolitinib) each target a specific cytokine node. Recombinant cytokines themselves are drugs too — IFN-α for hepatitis, G-CSF (filgrastim) to rebuild neutrophils after chemotherapy, IL-2 (aldesleukin) for metastatic melanoma.
• Their dysregulation is lethal. When the pro-/anti-inflammatory balance breaks, a cytokine storm follows — the fatal mechanism in severe sepsis, severe COVID-19, hemophagocytic lymphohistiocytosis, and CAR-T cell therapy's cytokine release syndrome. The same molecules that save you in the right dose can kill you in the wrong one.

Common misconceptions

• "Cytokines are made only by immune cells." Immune cells are the loudest producers, but endothelial cells, fibroblasts, keratinocytes, and epithelial cells all secrete cytokines. Stromal IL-6 and TNF-α are major drivers of chronic inflammation and the tumor microenvironment. Adipose tissue secretes leptin and IL-6, linking obesity to inflammation.
• "Each cytokine has one job." Cytokines are famously pleiotropic (one cytokine acts on many cell types with different effects) and redundant (several cytokines produce overlapping effects). IL-6 alone drives B-cell antibody production, hepatic acute-phase proteins, fever, and Th17 differentiation. That is also why single-cytokine knockouts are often buffered by the network.
• "Pro-inflammatory means bad." Inflammation is defense. IL-1, IL-6, and TNF-α are essential to clear infection and initiate repair; the danger is not their presence but their persistence and magnitude. Anti-inflammatory cytokines (IL-10, TGF-β) are not simply "good" either — chronic TGF-β drives fibrosis, and tumors exploit IL-10 to hide from immunity.
• "TNF-α causes cell death, so it is an executioner." TNF binding to TNFR1 usually activates NF-κB and inflammation (survival and cytokine production), not death. Apoptosis via caspase-8 is the minority outcome, engaged only when NF-κB signaling is blocked. TNF's dominant physiological role is orchestrating inflammation, not killing cells.
• "A cytokine's specificity lives in the cytokine." Specificity is set by the receptor. A cell responds only if it expresses the matching receptor chains, and many receptors share signaling subunits (the common γ-chain, gp130, the common β-chain). The information is in which receptors a cell displays, not in some private code inside the ligand.
• "Interferon is one molecule." There are three types. Type I (IFN-α has 13 subtypes, plus IFN-β) is the broad antiviral alarm signaling through IFNAR; type II is the single IFN-γ, made by T cells and NK cells to activate macrophages; type III (IFN-λ) uses a distinct receptor and protects mucosal epithelium with less systemic toxicity.

How cytokine signaling works

A cytokine's life is short and local. A stimulated cell — say a macrophage that has sensed a pathogen through a Toll-like receptor — transcribes and secretes the cytokine as a burst, often within an hour. The protein diffuses only a short distance before it is captured by a high-affinity receptor (dissociation constants typically 10 to 100 picomolar), which is why cytokines act at vanishingly low concentrations and over short ranges. If it binds a receptor on the same cell that made it, the signaling is autocrine (IL-2 sustaining a proliferating T cell is the classic example); on an immediate neighbor it is paracrine (the default mode); and in the rare cases it reaches the bloodstream to act on distant organs — IL-1 and IL-6 acting on the hypothalamus to raise a fever, or on the liver for the acute-phase response — it is endocrine.

Most cytokine receptors (the type I and type II receptor families, which bind interleukins and interferons) are catalytically dead: their cytoplasmic tails have no kinase domain. They solve this by borrowing a Janus kinase. Each receptor tail carries a pre-associated JAK (JAK1, JAK2, JAK3, or TYK2). When cytokine binding clusters two or more receptor chains together, their JAKs are brought into contact and trans-phosphorylate one another to switch on. The activated JAKs then phosphorylate specific tyrosines on the receptor tails, creating docking sites recognized by the SH2 domains of latent transcription factors called STATs (STAT1–STAT6). A recruited STAT is itself phosphorylated by the JAK, releases from the receptor, dimerizes with another phospho-STAT through reciprocal SH2–phosphotyrosine contacts, and translocates to the nucleus to bind GAS or ISRE promoter elements. From ligand binding to new transcription takes minutes. Different receptor–JAK–STAT pairings encode different outcomes: IFN-α/β activates a STAT1–STAT2–IRF9 complex (ISGF3), IFN-γ activates STAT1 homodimers, IL-4 activates STAT6, and IL-12 activates STAT4.

The pathway is deliberately self-limiting. Among the genes STATs switch on are the SOCS (suppressor of cytokine signaling) proteins, which bind the activated JAK-receptor complex and shut it down — a negative feedback brake. Phosphatases (SHP-1) and PIAS proteins add further restraint. Not every cytokine uses JAK-STAT: TNF-α and IL-1 signal through receptors that recruit adaptor proteins (TRADD/TRAF, MyD88) to activate NF-κB and MAP kinases, driving inflammatory gene programs; the TGF-β superfamily uses receptor serine/threonine kinases and SMAD transcription factors; and chemokines signal through G-protein-coupled receptors to reorganize the actin cytoskeleton and steer cell migration. The whole system runs as a network in which the balance of pro- and anti-inflammatory signals — not any single molecule — determines whether an immune response builds, holds, or resolves.

The four cytokine families compared

Family	Representative members	Main job	Receptor / pathway
Interleukins	IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17, IL-23	Leukocyte-to-leukocyte communication; shape T-helper fate, antibody production, inflammation	Mostly type I receptors → JAK-STAT (IL-1 family → MyD88/NF-κB)
Interferons	IFN-α, IFN-β (type I); IFN-γ (type II); IFN-λ (type III)	Antiviral defense; macrophage activation; MHC upregulation	Class II cytokine receptors → JAK-STAT (type I: JAK1/TYK2 → STAT1/STAT2; IFN-γ: JAK1/JAK2 → STAT1)
Tumor necrosis factors	TNF-α, lymphotoxin-α, FasL, RANKL, CD40L	Inflammation, cell survival vs apoptosis, bone remodeling, co-stimulation	TNFR superfamily → TRAF/TRADD → NF-κB (or caspase-8)
Chemokines	CXCL8 (IL-8), CCL2, CCL19/21, CXCL12, CX3CL1	Chemotaxis — direct leukocyte migration and homing	7-transmembrane GPCRs → G-protein → actin remodeling

Pro-inflammatory vs anti-inflammatory cytokines

Property	Pro-inflammatory	Anti-inflammatory / regulatory
Key members	IL-1β, IL-6, TNF-α, IFN-γ, IL-12, IL-17, IL-8	IL-10, TGF-β, IL-4, IL-13, IL-1Ra, IL-35, IL-37
Main sources	Macrophages, Th1/Th17, NK cells, neutrophils	Tregs, Th2, M2 macrophages, some B cells
Vascular effect	Endothelial activation, capillary leak, adhesion molecules	Dampen endothelial activation, restore barrier
Net immune effect	Recruit and activate leukocytes; amplify response	Suppress effectors; promote resolution and repair
When it goes wrong	Cytokine storm, sepsis, autoimmunity, chronic inflammation	Fibrosis (TGF-β), tumor immune evasion, chronic infection
Therapeutic angle	Blockade: anti-TNF, anti-IL-6R, anti-IL-17, JAK inhibitors	Delivery/mimetics for autoimmunity; blockade in cancer

Famous experiments and history

• Isaacs & Lindenmann discover interferon (1957). Working at the National Institute for Medical Research in London, Alick Isaacs and Jean Lindenmann showed that chick cells exposed to inactivated influenza virus released a soluble factor that made fresh cells resistant to live virus. They named it interferon because it interfered with viral replication — the founding cytokine of the antiviral system, published in Proceedings of the Royal Society B.
• Carswell & Old identify TNF (1975). Building on a century-old observation that some cancers regressed after bacterial infection (Coley's toxins), Elizabeth Carswell and Lloyd Old at Memorial Sloan Kettering found that serum from endotoxin-treated mice contained a factor that caused hemorrhagic necrosis of transplanted tumors. They named it tumor necrosis factor; it was cloned in 1984 and turned out to be a central driver of inflammation, not just tumor killing.
• IL-2 purified and cloned (early 1980s). T-cell growth factor, later renamed interleukin-2, was the first cytokine shown to sustain T-lymphocyte proliferation in culture — the discovery that let immunologists grow T cells indefinitely (Robert Gallo, Kendall Smith, and others). Tadatsugu Taniguchi cloned the human IL-2 gene in 1983, launching the recombinant-cytokine era; recombinant IL-2 (aldesleukin) became an FDA-approved therapy for metastatic melanoma and renal cell carcinoma.
• The JAK-STAT pathway mapped (early 1990s). James Darnell, George Stark, and Ian Kerr dissected interferon signaling using mutant cell lines that failed to respond to IFN, complementing them to identify the missing STAT and JAK components. Their work revealed the astonishingly direct membrane-to-nucleus route that most cytokine receptors use — and it directly enabled JAK inhibitor drugs decades later.
• Anti-TNF transforms rheumatology (1990s). Marc Feldmann and Ravinder Maini at the Kennedy Institute in London showed that TNF-α sat at the top of the inflammatory hierarchy in rheumatoid joints and that blocking it calmed the whole cascade. The first anti-TNF antibody trials in the mid-1990s produced dramatic remissions; infliximab was approved in 1998 and adalimumab in 2002. The boxed warning that anti-TNF reactivates latent tuberculosis proved, in patients, that TNF is essential to contain M. tuberculosis in granulomas.